Effects of cyclosporine A on clinical and histologic abnormalities in dogs with sebaceous adenitis.
OBJECTIVE
To evaluate the effects of cyclosporine A in the treatment of sebaceous adenitis in dogs.


METHODS
Open-label clinical trial.


METHODS
12 dogs with sebaceous adenitis.


METHODS
Dogs were treated with cyclosporine A at a dosage of 5 mg/kg/d (2.3 mg/lb/d), PO, for 12 months and reevaluated every 4 months. A clinical score was calculated by grading the extent of alopecia and severity of follicular casts as absent, mild, moderate, or severe in each of 17 body regions. Biopsy specimens were obtained and examined histologically and by means of immunohistochemical staining.


RESULTS
Mean clinical score was significantly decreased, compared with baseline score, after 4 months of treatment and remained low after 8 and 12 months. Histologically, the severity of inflammation was significantly decreased, as were numbers of macrophages, CD3+ T cells, and major histocompatibility complex class II-expressing cells. The percentage of hair follicles with sebaceous glands increased, suggesting regeneration of sebaceous glands. Clinical signs recurred when cyclosporine administration was discontinued.


CONCLUSIONS
Results suggest that administration of cyclosporine A at a dosage of 5 mg/kg/d may reduce the inflammation associated with sebaceous adenitis in dogs. Long-term treatment appears to be neccessary to control the disease.
Linek
Monika
M
Veterinary Clinic Linek, Brunnenkoppel 1, 22041 Hamburg, Germany.
Boss
Christina
C
Haemmerling
Renate
R
Hewicker-Trautwein
Marion
M
Mecklenburg
Lars
L
D000284:Administration, Oral; D000818:Animals; D016572:Cyclosporine / Q000627:therapeutic use*; D004283:Dog Diseases / Q000188:drug therapy* / Q000473:pathology; D004285:Dogs; D005260:Female; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008199:Lymphadenitis / Q000188:drug therapy / Q000473:pathology / Q000662:veterinary*; D008297:Male; D012627:Sebaceous Glands; D012720:Severity of Illness Index; D016896:Treatment Outcome
D007166:Immunosuppressive Agents; D016572:Cyclosporine